SS
CBIO

Steve Schonfeld’s Crescent Biopharma CBIO Stock Holding History

Steve Schonfeld’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-158
Closed -$60K – 1920
2020
Q4 		$60K Buy
+158
New +$55.4K ﹤0.01% 1488
2018
Q3 		– Sell
-1,400
Closed -$2.26M – 880
2018
Q2 		$2.26M Sell
1,400
-996
-42% -$1.71M 0.12% 249
2018
Q1 		$3.89M Sell
2,396
-2,104
-47% -$4.38M 0.29% 99
2017
Q4 		$7.56M Sell
4,500
-501
-10% -$662K 0.62% 29
2017
Q3 		$7M Sell
5,001
-409
-8% -$480K 0.64% 33
2017
Q2 		$6.04M Buy
+5,410
New +$4.47M 0.62% 31

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steve Schonfeld's CBIO Position: Q1 2021 in Review

Steve Schonfeld sold out of Crescent Biopharma (CBIO) in Q1 2021, closing a stake of 158 shares — an estimated $60K sold.

Steve Schonfeld first reported a position in CBIO in Q2 2017 and held it in 6 quarters. The position peaked at $7.56M in Q4 2017. 78 funds tracked by Wall St. Rank hold CBIO as of Q1 2021.

  • Steve Schonfeld reported no remaining Crescent Biopharma position as of Q1 2021 after selling out during the quarter.
  • Steve Schonfeld sold 158 Crescent Biopharma shares in Q1 2021, an estimated $60K.
  • Steve Schonfeld first reported a position in Crescent Biopharma in Q2 2017 and held it in 6 quarters.
  • Steve Schonfeld's Crescent Biopharma position peaked at $7.56M in Q4 2017.
  • 78 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2021, filed 17 May 2021.